Amedisys (AMED) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: 4.92%
• EPS Growth: -7.34%
• Country: US
• Employees: 19,000
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $105.50
• Price Target Upside: 4.47% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 73 Outperform
• Price Target: $110.00 ▲(8.92% Upside)

Amedisys exhibits strong financial performance and positive corporate developments, such as the pending merger with UnitedHealth Group. However, the high P/E ratio suggests potential overvaluation, and the absence of dividend yield limits income attractiveness. Technical indicators show a bullish trend, supporting a positive outlook.

Amedisys Business Overview & Revenue Model

Company Description

Amedisys, Inc. is a leading healthcare company providing home health care and hospice services across the United States. Founded in 1982 and headquartered in Baton Rouge, Louisiana, Amedisys operates through two primary segments: Home Health Care and Hospice Care. The company focuses on delivering high-quality, patient-centered care to individuals in the comfort of their homes, with services that include skilled nursing, physical therapy, and support for chronic illnesses, as well as end-of-life care.

How the Company Makes Money

Amedisys generates revenue primarily through reimbursement for its home health and hospice services. The company is paid by Medicare, Medicaid, and private insurance plans for the care provided to patients. Key revenue streams include payments for home health care services, which are typically based on a bundled payment model, and hospice services that are funded through per diem payments. Additionally, Amedisys benefits from partnerships with healthcare providers and referrals from hospitals, which help to drive patient volume and enhance service offerings. The increasing demand for home-based care solutions, particularly among aging populations, further contributes to the company's earnings potential.

Amedisys Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Amedisys Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 100.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMED, the sentiment is Positive. The current price of 100.99 is above the 20-day moving average (MA) of 98.99, above the 50-day MA of 97.76, and above the 200-day MA of 93.41, indicating a bullish trend. The MACD of 1.02 indicates Negative momentum. The RSI at 74.65 is Negative, neither overbought nor oversold. The STOCH value of 98.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMED.

Amedisys Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADUS	80 Outperform	$2.10B	25.18	8.54%	―	14.29%	7.85%
AMED	73 Outperform		―	7.26%	―	4.92%	-7.34%
ASTH	72 Outperform	$1.51B	58.68	3.50%	―	51.97%	-64.10%
PNTG	71 Outperform	$838.82M	31.04	11.44%	―	30.58%	24.86%
AVAH	59 Neutral	$1.60B	101.99	42.49%	―	11.53%	―
EHAB	53 Neutral	$402.48M	―	-21.72%	―	-0.39%	-1408.40%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%

Amedisys Corporate Events

Amedisys Completes Merger and Delists from Nasdaq

On August 14, 2025, Amedisys completed a merger that led to significant changes in its financial and operational structure. The company terminated its existing credit agreement, paid off its outstanding obligations, and delisted its common stock from Nasdaq. The merger also resulted in the conversion of equity awards and the resignation of the board of directors, marking a substantial shift in the company’s governance and shareholder rights.

The most recent analyst rating on (AMED) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Amedisys stock, see the AMED Stock Forecast page.

Amedisys and UnitedHealth Resolve Merger Opposition

On August 7, 2025, Amedisys, Inc. and UnitedHealth Group reached an agreement with the U.S. Department of Justice and several state Attorneys General to resolve opposition to their merger. The proposed final judgment requires certain divestitures and is subject to judicial approval to ensure it serves the public interest, with the merger’s completion contingent on meeting specified conditions.

The most recent analyst rating on (AMED) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Amedisys stock, see the AMED Stock Forecast page.

Amedisys Reports Q2 2025 Financial Results Amid Merger

On July 29, 2025, Amedisys reported its financial results for the second quarter of 2025, showing an increase in net service revenue to $621.9 million, up from $591.2 million in 2024. Despite merger-related expenses, the company’s adjusted EBITDA rose to $80.8 million, and adjusted net income per diluted share increased to $1.54. The company is in the process of merging with UnitedHealth Group and will not conduct a quarterly earnings call due to this pending merger. This financial performance highlights Amedisys’s resilience and growth amidst merger activities, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (AMED) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Amedisys stock, see the AMED Stock Forecast page.